
ALT The image is a cover of the NEJM Catalyst journal, Volume 7, Number 12, titled "Innovations in Care Delivery." It features a stylized illustration with various healthcare-related icons, such as a hospital, a phone, and a prescription symbol. The date "12/26" is prominently displayed in the center. The top left has a label "New Issue," and at the bottom, there is text urging readers to visit catalyst.nejm.org.

ALT Bar chart titled "Limits to AI Substitution across Specialties: Composition of Medicare Part B Payments Including E&M Services." The chart shows percentages of "Physical," "E&M," and "Nonphysical" services across 15 medical specialties and all overall (US$44.9bn). Total 2023 Medicare Part B payments are shown in parentheses (US$ bn); amounts are in billions of U.S. dollars.

ALT The image is page 1 of the Public Health Alerts report "Outcomes among Pregnant Women with Measles and Their Infants in the United States — Preliminary Analysis, 2025–2026" published in NEJM Evidence in partnership with Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. A slate banner at the bottom encourages readers to access the full report at evidence.nejm.org.

ALT The image contains six graphs. Graph A: The cumulative incidence of four-component primary end point of major adverse cardiovascular events (MACE) on treatment. Graph B: The cumulative incidence of three-component MACE on treatment. Graph C: The cumulative incidence of three-component MACE on treatment for composite of nonfatal MI, urgent coronary revascularization, or coronary heart disease (CHD) death. Graph D: The first and total_MACE events. Graph E: The cumulative incidence of the four-component MACE primary end point in landmark analysis with stratification of the pelacarsen group by lipoprotein(a) reduction after 3 months of treatment greater than or equal to and less than the median (170 nmol/l). Graph F: The cumulative incidence of the four-component MACE primary end point in landmark analysis with stratification of the pelacarsen group by achieved lipoprotein(a) after 3 months of treatment less than or equal to and greater than the median (69.5 nmol/l).

ALT The image features a quote: "I believe that patient selection will be essential in identifying those who would be most appropriate for the medication." Jennifer Rose V. Molano, M.D., reviewing Dauvilliers Y, et al. Oveporexton for narcolepsy type 1 — Results from two phase 3 trials. N Engl J Med 2026 Sep 24 The quote appears on a gradient blue background with the NEJM Clinician logo at the bottom.

ALT The image contains six graphs. Graph A: The cumulative incidence of four-component primary end point of major adverse cardiovascular events (MACE) on treatment. Graph B: The cumulative incidence of three-component MACE on treatment. Graph C: The cumulative incidence of three-component MACE on treatment for composite of nonfatal MI, urgent coronary revascularization, or coronary heart disease (CHD) death. Graph D: The first and total_MACE events. Graph E: The cumulative incidence of the four-component MACE primary end point in landmark analysis with stratification of the pelacarsen group by lipoprotein(a) reduction after 3 months of treatment greater than or equal to and less than the median (170 nmol/l). Graph F: The cumulative incidence of the four-component MACE primary end point in landmark analysis with stratification of the pelacarsen group by achieved lipoprotein(a) after 3 months of treatment less than or equal to and greater than the median (69.5 nmol/l).

ALT The image is a page from a publication titled "The IQEPS Model for Lean Hospital Facility Management: Standardization, Closed-Loop Repair, and Safety Governance During Multicampus Growth." It includes a framework diagram with four interconnected circles labeled Intelligence, Quality, Safeguard, and Effectiveness, surrounding a central circle labeled IQEPS Model for Lean Hospital Facility Management. Each circle contains brief descriptions of goals and functions, such as automation and standardized procedures. Above the image is the article type: The page also mentions NEJM Catalyst and the Massachusetts Medical Society.















